The front door of Alzheimer's diagnosis is leaving the specialist

The front door of Alzheimer's diagnosis is relocating from the neurology clinic to the family doctor's office, and the system around it has not yet caught up. Blood-based biomarker tests, clinical guidance that lets primary care physicians order and interpret them, and a new generation of disease-modifying drugs that work best when used early are aligning at the same moment. The result is a category of care that no longer needs a specialist to enter.

Palmqvist's real-world study of more than 1,300 patients across 165 physicians, presented at the Alzheimer's Association International Conference in London, found that primary care physicians and dementia specialists both reached a diagnostic accuracy of around 90% after reviewing the same blood test results. The Alzheimer's Association's new clinician guidance, released the same week, formalizes what that head-to-head match implies: the gate to an Alzheimer's workup is no longer a months-long wait for a neurologist, a PET scanner, or a spinal tap.

The mechanism is the relocated gate. A blood draw a primary care doctor can order, a result that is strongest as a rule-out rather than a confirmation, and a drug pipeline that punishes delay by definition. The specialist is not removed, but the specialist is no longer the door. Adults watching a parent's memory change can now ask their family doctor to start the conversation, with the caveat that the biomarker evidence base in diverse populations is still being built. The wait is not gone. It just moved.